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We have established functions of the stimulus-
dependentMAPKs, ERK1/2 andERK5, inDRG,motor
neuron, andSchwann cell development. Surprisingly,
many aspects of early DRG and motor neuron devel-
opment were found to be ERK1/2 independent, and
Erk5 deletion had no obvious effect on embryonic
PNS. In contrast,Erk1/2 deletion in developing neural
crest resulted in peripheral nerves thatweredevoid of
Schwann cell progenitors, and deletion of Erk1/2 in
Schwann cell precursors caused disrupted differenti-
ation and marked hypomyelination of axons. The
Schwann cell phenotypes are similar to those re-
ported in neuregulin-1 and ErbB mutant mice, and
neuregulin effects could not be elicited in glial precur-
sors lacking Erk1/2. ERK/MAPK regulation of myeli-
nation was specific to Schwann cells, as deletion in
oligodendrocyte precursors did not impair myelin
formation, but reduced precursor proliferation. Our
data suggest a tight linkage between developmental
functions of ERK/MAPK signaling and biological
actions of specific RTK-activating factors.INTRODUCTION
Nervous system development and function is dependent upon
a variety of soluble and membrane bound trophic stimuli, many
of which act through receptor tyrosine kinases (RTKs). Even
though more than 50 RTKs are present in the human genome,
a handful of signaling pathways are repeatedly implicated in
downstream cellular responses, particularly the MAPK, PI-3
kinase, JAK-STAT, and PLC pathways. Surprisingly, there has
been little progress in assigning specific developmental func-
tions to individual pathways (Lemmon and Schlessinger, 2010).
Indeed, the many in vitro studies carried out with pharmacolog-
ical inhibitors clearly predict that these signaling cascades
integrate the effects of multiple extracellular signals and thatelimination of even a single pathway in vivo would result in
complex, difficult to interpret phenotypes.
MAPK signaling generally refers to four cascades, each
defined by the final tier of the pathway: extracellular signal-regu-
lated kinases 1 and 2 (ERK1 and 2), ERK5, c-Jun N-terminal
kinases (JNK), and p38 (Raman et al., 2007). ERK1 and ERK2
(ERK1/2) exhibit a high degree of similarity and are considered
functionally equivalent, although isoform-specific effects have
been described. In the nervous system, ERK1/2 and ERK5 are
the primary MAPK cascades activated by trophic stimuli and
have been shown to mediate proliferation, growth, and/or
survival in specific contexts (Nishimoto andNishida, 2006). Aber-
rant ERK1/2 signaling plays a primary role in a range of human
syndromes that affect the nervous system, particularly the family
of ‘‘neuro-cardio-facial-cutaneous’’ (NCFC) syndromes (Ben-
tires-Alj et al., 2006). The precise role of ERK1/2 in the neurode-
velopmental abnormalities that characterize these disorders is
only now being investigated (Newbern et al., 2008; Samuels
et al., 2008, 2009). Indeed, most of our understanding of ERK
function is derived from in vitro models in the context of isolated
trophic stimuli. Such studies provide support for involvement of
ERK/MAPK signaling in almost every aspect of neural develop-
ment and function. However, the physiological relevance of
many in vitro findings has not been adequately tested, and
much less is knownabout ERK functions in the context ofmultiple
extracellular signals, as occurs in vivo.
The PNS has been the standardmodel system for defining bio-
logical actions of many neurotrophic molecules. The PNS princi-
pally derives from the neural crest, which generates sensory and
sympathetic neurons, satellite glia within the DRG, and Schwann
cells within the peripheral nerve. Peripheral neuron development
requires trophic signaling via neurotrophins and GDNF family
members, which act via RTKs that activate ERK1/2 (Marmigere
and Ernfors, 2007). Analyses of PNS neuronal development
in vitro have shown that ERK1/2 signaling is important for differ-
entiation and neurite outgrowth in response to neurotrophins,
other trophic factors, and ECM molecules (Atwal et al., 2000;
Klesse et al., 1999; Kolkova et al., 2000; Markus et al., 2002).
ERK1/2 activation by some of these same molecules has been
implicated in regulating neurite outgrowth from motor neurons,
which also extend axons in peripheral nerves (Soundararajan
et al., 2010). Many trophic stimuli also activate ERK5, whichNeuron 69, 91–105, January 13, 2011 ª2011 Elsevier Inc. 91
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Specific Functions for ERK/MAPK in PNS Developmentappears to be involved in neuronal survival in the PNS, particu-
larly in the context of NGF-mediated retrograde signaling (Fine-
gan et al., 2009; Watson et al., 2001). These findings plainly
predict that disruption of either the ERK1/2 or ERK5 pathway
in vivo would result in profound defects in neuronal differentia-
tion, survival, and/or developmental axon growth.
Schwann cell development is also critically dependent on
extracellular factors that act through RTKs, including neuregu-
lins, PDGF, IGFs, FGFs, and ECM components (Jessen and
Mirsky, 2005). These factors are capable of activating PI3K,
PLC, ERK1/2, and ERK5 signaling (Lemmon and Schlessinger,
2010). However, the role of ERK5 in glia has not been assessed
and the data regarding ERK1/2 function in Schwann cell devel-
opment are controversial. ERK1/2 has been shown to regulate
the survival of early Schwann cell progenitors (SCPs) andmature
Schwann cells in vitro; however, other research has not sup-
ported these findings (Dong et al., 1999; Li et al., 2001; Parkinson
et al., 2002). Some evidence suggests ERK1/2 signaling regu-
lates Schwann cell myelination, yet other careful studies found
little effect and argue that PI3K/Akt signaling plays amore central
role (Harrisingh et al., 2004; Hu et al., 2006; Maurel and Salzer,
2000; Ogata et al., 2004). The reasons for these discrepancies
are unclear and the precise role of ERK1/2 signaling in Schwann
cell development remains unresolved.
Here, we have defined the roles of ERK1/2 and ERK5 in
neuronal and glial development in vivo. In vivo analyses have
previously been hampered by the strong redundancy between
ERK1 and ERK2 and the early embryonic lethality of Erk2 and
Erk5 knockouts (Nishimoto and Nishida, 2006). To circumvent
these issues we have utilized a combination of Erk2 conditional
and Erk1 null alleles to eliminate ERK1/2 signaling in vivo, and
have generated an Erk5 conditional allele. We demonstrate
that Erk1/2 and Erk5 are surprisingly dispensable for many
aspects of prenatal DRG and motor neuron development
in vivo, although Erk1/2 deletion in DRG neurons compromises
sensory axon innervation in NGF-expressing target fields. In
contrast, Erk1/2 signaling is essential at multiple stages of
Schwann cell development and is required for PNS myelination.
Our data constrain interpretation of themany prior in vitro studies
and suggest tight linkage between ERK/MAPK functions in vivo
and biological actions of specific RTK activating factors.
RESULTS
ERK1/2, but Not ERK5, Deletion in the Embryonic PNS
Results in DRG Degeneration
To establish the role of ERK1/2 in embryonic PNS development,
we generated Erk1/ Erk2fl/fl Wnt1:Cre (hereafter referred
to as Erk1/2CKO(Wnt1)) and Mek1fl/fl Mek2/ Wnt1:Cre (Mek
1/2CKO(Wnt1)) mice. The Wnt1:Cre driver induces recombination
at E8.5 in pluripotent neural crest cells, which generate both
neuronal and glial components of the PNS (Danielian et al.,
1998).We have previously characterizedmajor defects in cranio-
facial and cardiac neural crest derived structures by E10.5 and
embryonic lethality between E18 and E19 in Erk1/2CKO(Wnt1)
and Mek1/2CKO(Wnt1) mice (Newbern et al., 2008). However,
DRGs in E10.5 Erk1/2CKO(Wnt1) embryos appear to be morpho-
logically intact (see Figures S1A and S1B available online).92 Neuron 69, 91–105, January 13, 2011 ª2011 Elsevier Inc.ERK1/2 expression is significantly reduced in the DRG
by E10.5, and western blotting of E12.5 Erk1/2CKO(Wnt1) or
Mek1/2CKO(Wnt1) DRG lysates shows a near-complete loss of
ERK1/2 or MEK1/2 protein, respectively (Figures S1C–S1E).
RSK3, a downstream substrate of ERK1/2, showed significantly
reduced phosphorylation further indicating functional inactiva-
tion of ERK1/2 signaling (Figure S1E).
We therefore utilized Erk1/2CKO(Wnt1) mice to ask whether the
loss of Erk1/2 disrupts PNS development in vivo. Compared to
controls (Figures 1A and 1C), massive cell loss was observed
at both brachial and lumber levels in E17.5 Erk1/2CKO(Wnt1)
DRGs (Figures 1B, 1D, and S1F–S1J). We found that homozy-
gous deletion of both genes was necessary for the decreased
neuronal number in the DRG (data not shown). E17.5
Mek1/2CKO(Wnt1) embryos show a qualitatively similar, though
more severe phenotype, than in stage matched Erk1/2CKO(Wnt1)
embryos (Figures S1F–S1H). Endogenous levels of MEK1/2
protein are reported to be lower than ERK1/2, likely resulting in
more rapid protein clearance following recombination and a
relatively accelerated phenotypic onset (Ferrell, 1996). Whole-
mount neurofilament immunolabeling of E15.5 control and
Erk1/2CKO(Wnt1) forelimbs revealed that nearly all peripheral
projections are absent in mutant forelimbs (Figures 1E and 1F).
It is notable that motor neurons do not undergo recombination
in the Wnt1:Cre line, yet their projections totally degenerate.
Overall, these data demonstrate that inactivation of Erk1/2 in
the PNS results in the loss of all peripheral projections and
massive DRG neuron death.
ERK5 is another well-known stimulus-dependent MAPK
under trophic control during PNS development (Watson et al.,
2001). We tested the role of this pathway in Erk5fl/fl Wnt1:Cre
(Erk5CKO(Wnt1)) mice (Figure S1K–S1N). In contrast to
Erk1/2CKO(Wnt1) mice, Erk5CKO(Wnt1) mice are viable and able
to breed. However, Erk5CKO(Wnt1) adult mice are smaller than
controls and exhibit external ear truncation and mandibular
shortening, likely due to an alteration in the development of
the craniofacial neural crest (Figure S1M). Perhaps surprisingly,
markers for proprioceptive (Parvalbumin) and nociceptive
(CGRP and TrkA) sensory neurons, exhibited relatively normal
expression in P1 Erk5CKO(Wnt1) DRGs (Figures 1G–1J and data
not shown). Whole-mount neurofilament immunolabeling did
not reveal any deficit in the peripheral projections of E14.5
Erk5CKO(Wnt1) forelimbs compared to controls (Figures 1K–1L).
Both CGRP and Parvalbumin positive central afferents within
the spinal cord appeared intact as well (Figures 1G–1J). Overall,
these data suggest that ERK5 does not play a primary role in
early aspects of PNS morphogenesis in vivo.
Erk1/2 Is Required for Schwann Cell Progenitor
Development
In order to determine the precise developmental defect un-
derlying the massive decrease in DRG size observed in
E17.5 Erk1/2CKO(Wnt1) embryos, we assessed the expression of
neuronal and glial markers at earlier stages of development.
Within the DRG of E10.5–12.5 Erk1/2CKO(Wnt1) embryos, appro-
priate neuronal (neurofilament, NeuN, TrkA, Brn3a, Tau, and
Islet1/2) markers are expressed (Figures 2A–2D, 3, and S3), sug-
gesting that early stages of neuronal specification are intact in
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Figure 1. Deletion ofErk1/2, but Not Erk5, in
the PNS Results in DRG Neuron Loss and
the Absence of All Peripheral Projections
(A–D) Compared to wild-type (A and C), E17.5
Erk1/2CKO(Wnt1) (B and D) L4 DRG cross-sections
revealed a massive decrease in DRG size as indi-
cated by the gross morphology and decreased
number of cells expressing neuronal markers
(scale bar = 50 mm).
(E and F) Whole-mount neurofilament labeling of
E15.5 control (E) and mutant (F) embryos revealed
only sparse labeling in Erk1/2CKO(Wnt1) forelimbs,
demonstrating that both motor and sensory
projections are absent (scale bar = 100 mm).
(G–J) Analysis of the expression of Parvalbumin and
CGRP in P1 control (G and I) and Erk5CKO(Wnt1)
(H and J) lumbar DRG cross sections did not
show any gross change in DRG sensory neurons
or in central projections within the spinal cord
(arrows) (scale bar = 50 mm).
(K–L) Whole-mount neurofilament immunolabeling
of E14.5 control (K) and Erk5CKO(Wnt1) (L) forelimbs
showed no differences in peripheral axon growth
(scale bar = 100 mm).
See also Figure S1.
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Figure 2. ERK1/2 Is Required for the Development of SCPs In Vivo and Mediates Neuregulin-1 Signaling In Vitro
(A–D) The expression of neuronal and glial markers is grossly normal within control (A and C) and Erk1/2CKO(Wnt1) (B and D) brachial DRGs at E10.5 and E12.5.
(E and F) Sox2 positive glial progenitors entering the neurofilament stained peripheral nerve are readily detectable in cross-sections of the brachial region of E12.5
wild-type embryos (E). However, E12.5 Erk1/2CKO(Wnt1) embryos exhibit a near complete absence of glial progenitors in the peripheral nerve (F, arrowheads) (scale
bar = 50 mm).
(G–I) Glial progenitors cultured from E11.5 control DRGs (G and I) can be sustained by Type III neuregulin-1 in vitro. The effect of neuregulin-1 on glial progenitor
survival is essentially absent in Erk1/2CKO(Wnt1) (H and I) cultures after 1 DIV (mean ± SEM; *p < 0.001). DNA staining revealed a large number of pyknotic, presum-
ably dying glial progenitors in mutant cultures at this time point (arrowheads).
(J–M) Egr2/Krox-20 immunolabeling labels the BC in the proximal segments of control (J) E12.5 peripheral nerves. Egr2/Krox-20 expressing cells are nearly
absent in Erk1/2CKO(Wnt1) (K) ventral roots (arrowheads). A number of Islet1/2 positive neurons are present within the ventral root and proximal peripheral nerve
of E12.5 Erk1/2CKO(Wnt1) (M) embryos (arrowheads).
See also Figure S2.
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Figure 3. Axons Extend Normally following
Erk1/2 or Mek1/2 Inactivation in the PNS
but Are Defasciculated
(A–D)Whole-mount neurofilament immunolabeling
was utilized to examine peripheral nerve out-
growth in the forelimb. Compared to littermate
controls (A and C), Erk1/2CKO(Wnt1) (B and D)
embryos demonstrated a normal extent of axon
outgrowth up to E12.5, however, the mutant
nerves were defasciculated (inset in D).
(E and F) Similar results were obtained in E12.25
Mek1/2CKO(Wnt1) (F) embryos.
Scale bar = 100 mm, ax = axillary n., ra = radial n.,
mu = musculocutaneous n., me = median n., ul =
ulnar n. See also Figure S3.
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Specific Functions for ERK/MAPK in PNS Developmentthese embryos. The pattern of two markers of glial differentia-
tion, Sox2 and BFABP, within the DRG of E10.5–E12.5
Erk1/2CKO(Wnt1) embryos also appeared normal suggesting
satellite glia are appropriately specified (Figures 2A–2D, S2C,
and S2D).
In striking contrast, we noted a marked loss of Sox2 and
BFABP labeled Schwann cell progenitors (SCPs) within the
peripheral nerve of E11.5–12.5 Erk1/2CKO(Wnt1) embryos (Figures
2E, 2F, and S2A–S2D). Generic labeling of all cells with Hoechst
(Figures 2E and 2F) or Rosa26LacZ (Figures S2E and S2F) shows
a similar pattern demonstrating loss of cells rather than changes
in the expression levels of these specific glial markers. These
data indicate that ERK1/2 is required for SCP colonization of
the peripheral nerve in vivo.
SCPs are heavily reliant upon neuregulin/ErbB signaling,
a potent activator of the ERK1/2 pathway (Birchmeier and
Nave, 2008). Mice lacking Nrg-1, ErbB2, or ErbB3 exhibit an
absence of SCPs in the developing nerve (Birchmeier and
Nave, 2008). Nrg-1 or ErbB2 gene expression was not
decreased in E12.5 Erk1/2CKO(Wnt1) DRGs (Figure S2G). We
tested whether the disruption of SCP development was due to
a glial cell-autonomous requirement for ERK1/2 in neuregulin/
ErbB signaling. Glial progenitors from E11.5 Erk1/2CKO(Wnt1)
DRGs were cultured in the presence of neuregulin-1. The loss
of Erk1/2 clearly abolished the survival promoting effect of
neuregulin-1 in vitro (Figures 2G–2I). These data indicate that
ERK1/2 is required for glial responses to neuregulin-1, which
likely contributes to the failure of SCP development in vivo.
It has been previously shown that the neural crest derived,
boundary cap (BC) generates SCPs and establishes ECM bound-
aries that prevent the migration of neuronal cell bodies into the
peripheralnerve (Bronetal., 2007;Maroetal., 2004).WeexaminedNeuron 69, 91–10this gliogenic niche in Erk1/2CKO(Wnt1)
embryos by immunostaining for Egr2/
Krox-20, which is expressed by the BC.
Interestingly, the proximal ventral root of
E12.5 Erk1/2CKO(Wnt1) embryos exhibited
a near complete absence of Egr2/Krox-
20-expressing BC cells (Figures 2J
and 2K). We also noted Islet1/2 positive
neuronal bodies in the ventral root of
E11.5–12.5 Erk1/2CKO(Wnt1) embryos,further indicating a failure in function (Figures 2L and 2M). Overall,
these data suggest that the defect in SCP development is due in
part to a disruption in a gliogenic niche.
Initial Stages of SensoryAxonOutgrowthDoNotRequire
Erk1/2
A key consequence of the loss of SCPs in Nrg-1/ErbB mutant
mice is nerve defasciculation, loss of all peripheral projections,
and neuron death (Meyer and Birchmeier, 1995; Morris et al.,
1999; Riethmacher et al., 1997). Indeed, the absence of SCPs
likely contributes to the complete loss of motor projections in
E15.5 Erk1/2CKO(Wnt1) embryos, since recombination in motor
neurons is not induced by Wnt1:Cre (Figures 1E and 1F).
However, the ERK1/2 signaling pathway plays a central role in
the response to numerous axon growth promoting stimuli. We
predicted that DRG neuron outgrowth in Erk1/2CKO(Wnt1)
embryos would be disrupted, prior to the point when the loss
of SCPswould affect neuronal development. Thus, we examined
the temporal dynamics of axon outgrowth and DRG neuron
number in Erk1/2CKO(Wnt1) embryos.
We first examined changes in neuron number in these
embryos. At E11.5, when SCP number in the peripheral nerve
is reduced, no pyknotic nuclei were detected in the DRG. By
E12.5, occasional pyknotic nuclei and increased caspase-3
activity were detected in Erk1/2CKO(Wnt) rostral DRGs (Figures
S3A, S3B, and S3F). However, relative counts of Islet1/2 positive
neurons in brachial DRGs at E12.5 did not reveal a statistically
significant difference (Figure S3E). We examined neuronal
number with a Tauloxp-STOP-loxp-mGFP-IRES-nlsLacZ (TauSTOP)
reporter line in E15.5 mutants and found only 19.6% ± 4.1% of
nls-LacZ expressing neurons remained (Hippenmeyer et al.,
2005; Figures S3C–S3E). The time course of neuronal death5, January 13, 2011 ª2011 Elsevier Inc. 95
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Specific Functions for ERK/MAPK in PNS Developmentclosely mirrors that reported in ErbB-2 or -3 null mice (Morris
et al., 1999; Riethmacher et al., 1997). Thus, neurogenesis is
relatively unaffected by the loss Erk1/2, however, neuronal death
is initiated after E12.5, likely an indirect effect resulting from
disruption of the SCP pool.
The pattern of early peripheral nerve growth in Erk1/2CKO(Wnt1)
embryos was evaluated with whole mount neurofilament immu-
nolabeling, which labels all peripheral projections of sensory,
motor, or sympathetic origin. In contrast to our predictions, the
extent of initial axonal outgrowth in Erk1/2CKO(Wnt1) embryos ap-
peared normal at E10.5 and E12.5 (Figures 3A–3D). At E12.5,
nerves were disorganized and defasciculated in the forelimb,
similar to what has been observed in Nrg-1/ErbB mutant mice
(Figures 3C and 3D). Comparable results were obtained with
Mek1/2CKO(Wnt1) embryos (Figures 3E and 3F), though again defi-
cits appeared slightly earlier when compared to Erk1/2CKO(Wnt1)
embryos. A specific defect in sensory neuron outgrowth could
be masked by neurofilament expression in motor axons. This
possibility was excluded by analyzing two sensory-neuron-
specific reporter lines, the TauSTOP reporter line, which does
not label motor neurons inWnt1:Cre mice, and the Brn3aTauLacZ
mouse (Eng et al., 2001; Hippenmeyer et al., 2005). Both
reporter lines revealed that sensory neuron outgrowth in E12.5
Erk1/2CKO(Wnt1) embryos is of relatively normal extent, but defas-
ciculated (Figures S3G–S3J). In summary, these data indicate
that in the absence of ERK1/2, neuronal number, and the extent
of axon outgrowth are intact up to E12.5. Following this stage,
a number of neuronal defects are evident, which are consistent
with the loss of SCPs in this model, namely, defasciculation,
the overt loss of all peripheral projections, and sensory neuron
death.
Erk1/2 Is Required for NGF-Dependent Cutaneous
Innervation
The requirement of SCPs for ERK1/2 and the potential for
complex neuron-glial interactions in the context of neural crest
Erk1/2 deletion, limited our analysis of neuronal roles for
ERK1/2 signaling. To better understand neuronal ERK1/2, we
employed two additional Cre lines. Nestin:Cre induces recombi-
nation in progenitors throughout the CNS and leads to geneFigure 4. Neuron-SpecificDeletion ofErk1/2 orMek1/2DoesNot Alter I
vation
(A and B) Compared to littermate controls (A), E14.5Mek1/2CKO(Nestin) (B) forelimb
mount neurofilament immunolabeling.
(C and D) P0 DRGs inMek1/2CKO(Nestin) (D) mice appear morphologically similar to
P2X3.
(E–H) Compared to controls (E and G), cutaneous innervation is reduced in P0Me
paws show a reduction in cutaneous afferents in the epidermis of mutant (F) mice.
controls (G) in flat mount readily labels the subepidermal plexus. Mek1/2CKO(Nest
(I–O) Relative to controls (I), a significant and persistent reduction in the numbe
Erk1/2CKO(Advillin) (J) mice, which is quantitated in (O) (mean ± SEM; *p < 0.001).
and the number of sensory neurons in the DRG were not significantly altered in t
(P–R) DRG neurons from E11.5 control and Erk1/2CKO(Wnt1) embryos were either
stained with neurofilament after 2DIV. In dissociated cultures, the length of the tot
in Erk1/2CKO(Wnt1) neurons (P) (mean ± SEM; n = >100 neurons in each condition f
a significant reduction (p < 0.001) in the extent of NGF induced neuronal outgrow
pendent cultures is reported.
See also Figure S4.deletion in both neuronal and glial populations. However, recom-
bination in the DRG occurs beginning atE10.5 resulting in gene
deletion in most DRG neurons, but not in Schwann cells (Kao
et al., 2009; Tronche et al., 1999; Zhong et al., 2007). The
Advillin:Cre line induces recombination in virtually all DRG and
trigeminal ganglion neurons beginning at E12.5 and is almost
exclusive for these populations (Hasegawa et al., 2007).
Mek1/2CKO(Nes) mice die shortly after birth and major reduc-
tions in MEK1/2 expression and ERK1/2 activation were noted
in the Mek1/2CKO(Nes) DRG by E14 (Figure S4A). Whole-mount
neurofilament labeling at mid-embryonic stages revealed
a normal pattern of early peripheral nerve development in the
absence of Mek1/2 (Figures 4A and 4B). DRG morphology is
grossly normal at birth and the expression of nociceptive
markers, P2X3 and TrkA, and the proprioceptive marker, Parval-
bumin, are relatively unchanged (Figures 4C and 4D and data not
shown). In the target field, the main nerve trunks of P0
Mek1/2CKO(Nes) peripheral nerves were relatively normal in size;
however, we noted a reduction in the innervation of the subepi-
dermal plexus and the number of cutaneous fibers entering the
epidermal field (Figures 4E–4H). These data show that the early
loss of ERK1/2 signaling in DRG neurons does not modify initial
stages of axon outgrowth, but inhibits axon innervation of the
cutaneous fields by birth.
Erk1/2CKO(Advillin) mice are indistinguishable from controls in
the days following birth. However, by the end of the first post-
natal week, mutant mice are noticeably smaller and the mice
do not survive past three weeks of age. Importantly, the number
of fibers innervating the epidermis in P3 Erk1/2CKO(Advillin) hin-
dlimbs was significantly decreased relative to controls (Figures
4I, 4J, and 4O). At this time point, a relatively normal number of
DRG neurons were present, which exhibit a typical pattern of
TrkA and CGRP expression and complete loss of ERK2 expres-
sion (Figures 4M and 4N and data not shown). CGRP labeled
central afferents also appeared intact in the dorsal spinal cord
of mutant mice (Figures 4K and 4L). In P18mutants, DRG neuron
number was 41.5% ± 3.0% (n = 2) of littermate controls. This is
likely an indirect phenotype related to the decrease in cutaneous
innervation, which diminishes trophic support. Taken together,
these data demonstrate that DRG neuron specific inactivationnitial AxonExtension, but DisruptsNGF-Dependent Cutaneous Inner-
s exhibit normal growth of major peripheral nerve trunks as detected by whole
controls (C) and exhibit relatively normal expression of the nociceptive marker
k1/2CKO(Nestin) (F and H) mice. PGP9.5 labeling of cross-sections from P0 fore-
Whole-mount GFP immunolabeling of skin derived from the trunk of P0 TauSTOP
in) (H) mice exhibit significant reductions in innervation.
r of PGP9.5 labeled epidermal afferents was detected in the hindlimb of P3
However, CGRP-labeled central afferents in the dorsal spinal cord (K and L)
he P3 Erk1/2CKO(Advillin) dorsal spinal cord (M and N).
dissociated (P) or explanted (Q and R), cultured in the presence of NGF, and
al and longest neurites demonstrated a significant decrease in both parameters
rom three independent cultures; *p < 0.001). Erk1/2CKO(Wnt1) explants exhibited
th. The average hemidiameter length ± SEM of >20 explants from three inde-
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Neuron
Specific Functions for ERK/MAPK in PNS Developmentof ERK1/2 signaling is not necessary for initial stages of axon
outgrowth in vivo but is required for superficial cutaneous
innervation.
Arborization within superficial cutaneous target fields is known
to be dependent upon NGF/TrkA signaling (Patel et al., 2000).
The link between ERK1/2 and NGF was further assessed
in vitro. Indeed, both dissociated and explanted DRG neu-
rons from Erk1/2CKO(Wnt) and Mek1/2CKO(Nes) embryos exhibit
decreased axon outgrowth in response to NGF (Figures 4P–4R
and data not shown). Thus, the deficit in cutaneous innervation
observed in vivo is likely mediated by a disruption of NGF/TrkA
signaling.
Though cutaneous innervation was clearly deficient, various
aspects of proprioceptive morphological development ap-
peared qualitatively normal in P3 Erk1/2CKO(Advillin) mice,
including central projections into the spinal cord, and the inner-
vation of muscle spindles within the soleus (Figures S4E–S4L).
However, these finding should be interpreted with caution as
the proprioceptive system develops relatively early related to
the recombination induced by Advillin:Cre. Indeed, the mice
develop an abnormality of spindle innervation and exhibit
a hindlimb clasping phenotype when raised by the tail beginning
in the second postnatal week (Figures S4B–S4D). These findings
suggest that ERK/MAPK signaling is required for some
aspects of proprioceptive development, possibly downstream
of NT-3.
The ERK1/2 and ERK5 signaling pathways have been shown
to modify similar substrates (Nishimoto and Nishida, 2006).
Thus, compensatory interactions between ERK1/2 and ERK5
might mask a requirement for the other pathway in Erk1/2 or
Erk5 mutants. In order to test whether Erk1/2 and Erk5 exhibit
compensatory interactions in DRG neurons, we generated
Erk1/ Erk2fl/fl Erk5fl/fl Advillin:Cre mice. The added deletion of
Erk5 does not appear to strongly modify the Erk1/2 deletion
phenotypes. Thus, Erk1/2/5 triple mutants exhibit a hindlimb
clasping phenotype and die at the same postnatal ages as
Erk1/2 double mutants. These data suggest that the ERK1/2
and ERK5 pathways do not significantly compensate for one
another during DRG neuron development.
Peripheral Myelination Requires Erk1/2 Signaling
The effects of ERK1/2 on the establishment of the SCP pool
precluded analyses of later stages of Schwann cell develop-
ment, particularly myelination. To this end, we utilized the Desert
hedgehog:Cre knockin mouse, which induces recombination at
E13, almost exclusively in the Schwann cell lineage (Jaegle
et al., 2003). Loss of ERK1/2 occurs after the specification of
the SCP pool and during the transition into immature Schwann
cells (Jessen and Mirsky, 2005). Erk1/2CKO(Dhh) mice were born
at normal Mendelian ratios but exhibited tremor and hindlimb
paresis within 2 weeks of birth and do not survive past the fourth
postnatal week. Western blotting of mutant P1 sciatic nerve
lysates revealed a significant decrease in the expression of
ERK1/2 (Figure S5A). Whole-mount LacZ staining of control
embryos crossed with Rosa26LacZ demonstrates recombination
within the proximal peripheral nerve by E13.5 and most of the
sciatic nerve by E14.5 (data not shown). E15.5 Erk1/2CKO(Dhh)
Rosa26LacZ embryos showed a morphologically similar pattern98 Neuron 69, 91–105, January 13, 2011 ª2011 Elsevier Inc.of recombination and peripheral nerve patterning as littermate
controls (Figures 5A and 5B). The distribution of Schwann cells
in themature, P20 Erk1/2CKO(Dhh) Z/EG phrenic nerve projections
appeared similar to controls, with Schwann cells present up to
the NMJ (Figures S5B and S5C). These finding suggest Schwann
cells take up relatively normal positions in Erk1/2CKO(Dhh)
embryos.
Although Schwann cells appeared to be present within the
nerve, gross dissection of P18, Erk1/2CKO(Dhh) sciatic nerves re-
vealed markedly decreased nerve caliber and increased translu-
cency (Figure 5C). Electron microscopy revealed a clear, striking
reduction in the number of myelinated axons and an increase in
the number of unmyelinated axons in Erk1/2CKO(Dhh) mice
(Figures 5D–5F). There was no change in the number of Schwann
cell nuclei within the sciatic nerve and dying, pyknotic nuclei
were not detected at this stage (Figure 5G). These data show
that loss of ERK1/2 in Schwann cell progenitors clearly inhibits
myelination.
The development of myelinating Schwann cells involves the
upregulation of numerous factors, including Egr2/Krox-20,
S100b, and various myelin components (Jessen and Mirsky,
2005). Immunohistochemical analysis of P18 Erk1/2CKO(Dhh)
sciatic nerves revealed a 77.8% ± 8.1% decrease in the number
of Egr2/Krox-20 positive cells and the expression of S100b was
nearly absent (Figures 5H–5K). GFAP immunolabeling of non-
myelinating Schwann cells appeared normal at this stage (data
not shown). These findings suggest that ERK1/2 is required for
the progression of the myelinating Schwann cell lineage after
initial specification.
ERK1/2 Regulates a Transcriptional Network Critical
to Schwann Cell Development
In order to better understand the potentially diverse develop-
mental mechanisms underlying ERK1/2 regulation of PNS devel-
opment, we performed microarray analysis on RNA extracts
derived from E12.5 Erk1/2CKO(Wnt1) and wild-type DRGs. We
did not detect overt changes in DRG neuron number at this
developmental stage, suggesting the profile is a reflection of
ERK1/2 regulated genes and not the loss of any particular cell
type. 209 distinct genes met our inclusion criteria, which
included 98 downregulated and 111 upregulated genes in
Erk1/2CKO(Wnt1) samples (Figures 6A and S6). Functional annota-
tion of regulated genes revealed significant changes in media-
tors of transcriptional regulation, cell-cell signaling, intracellular
signaling, and cell-cycle/division (Figures 6A and S6).
A number of genes involved in transcriptional regulation were
modified that have been shown to regulate glial development
(Figure 6B). Microarray changes were validated by qPCR of
DRG samples from E12.5 Erk1/2CKO(Wnt1) embryos (Figure 6C
and data not shown). Significantly decreased expression was
observed for Egr2/Krox-20, Id4, Id2, and Etv1/Er81, all of which
have been shown to be required for or modify myelinating glia
differentiation (Marin-Husstege et al., 2006; Topilko et al.,
1994). Surprisingly, mutant DRGs exhibited increased mRNA
levels of the myelin components, MBP and MAG. The increase
in MBP and MAG suggest that the loss of ERK1/2 signaling
may have triggered, in part, a molecular program of premature
differentiation.
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Figure 5. Schwann-Cell-Specific Erk1/2 Inactivation Results in
Hypomyelination
(A andB)Whole-mount LacZ staining of the trunk and hindlimb of E15.5 control
(A) and Erk1/2CKO(Dhh) (B) mice crossed with Rosa26LacZ show a similar pattern
of staining in the peripheral nerve, including the intercostal (arrowheads) and
sciatic (arrows) nerve.
(C) Upon gross dissection, the sciatic nerves of P18 Erk1/2CKO(Dhh) mice were
noticeably smaller in diameter and more transparent than control nerves.
(D–G) EM analysis of P18 sciatic nerve cross sections from control (D) and
Erk1/2CKO(Dhh) (E) mice show a dramatic reduction in the number of myelinated
axons and an increase in unmyelinated axons (yellow arrows) in mutant mice.
The total number of axons and Schwann cell nuclei in the nerve was not
changed (F and G) (mean ± SEM, *p < 0.01).
(H–K) Immunolabeling for markers of myelinating Schwann cell differentiation,
Egr2/Krox-20 (H and I) and S100b (J and K), was performed in P18 control and
Erk1/2CKO(Dhh) sciatic nerve cross-sections. A decrease in the number of
Egr2/Krox-20 positive cells and a massive reduction in S100b labeling were
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Specific Functions for ERK/MAPK in PNS DevelopmentRequirement for Erk1/2 in Motor Neuron and
Oligodendrocyte Development
In order to explore ERK1/2 regulation of another class of periph-
erally projecting neuron and to assess regulation of another type
of myelinating cell, we utilized an Olig2:Cre mouse to induce
recombination by E9.5 in the spinal cord progenitor domain
that produces motor neurons and oligodendrocytes (Dessaud
et al., 2007; Novitch et al., 2001). We first examined the develop-
ment of spinal motor neurons. Erk1/2CKO(Olig2) mice do not
survive past the first day of birth. Cre dependent reporter line
expression and a decrease in ERK1/2 expression were noted
in E14.5 motor neurons and the progenitor domain from which
they arise (Figures 7A, 7B, S7A, and S7B). Whole-mount immu-
nolabeling of the E14.5 mutant forelimbs revealed a normal
pattern of motor neuron outgrowth (Figures 7A and 7B). Motor
innervation of neuromuscular junctions (NMJs) in the soleus
and diaphragm also appeared intact in P1 Erk1/2CKO(Olig2) mice
(Figures 7C–7F). Thus, motor neuron axon development does
not appear to be at all dependent on ERK1/2 signaling during
embryonic development.
Given the profound effects on peripheral glial following the loss
Erk1/2 we analyzed the development of oligodendrocytes within
the spinal cord of Erk1/2CKO(Olig2) mice. A significant decrease in
the number of oligodendrocyte progenitors in the spinal cord
white matter was evident by E14.5. Quantification in the white
matter at E14.5 revealed that 51.1%± 4.9%of PDGF-Ra positive
cells remained in themutants while the number of S100b positive
cells at P1 was 41.2% ± 6.5% of controls (Figures 8A–8C, S8A,
and S8B). The total number of nuclei in the white matter was
similarly decreased in Erk1/2CKO(Olig2) embryos, indicating that
the defect is not due to altered expression of glial markers
(Figures 8A–8C). The number of oligodendrocytes thus appears
to be regulated by ERK1/2 signaling in vivo.
Oligodendrocyte proliferation in vivo is strongly regulated by
PDGF acting through the receptor tyrosine kinase, PDGF-Ra,
a known ERK1/2 activator (Calver et al., 1998). In exploring the
mechanism underlying the reduction in white matter glia, we
noted a significant decrease in the proportion of PDGF-Ra cells
colabeled with BrdU in E14.5 Erk1/2CKO(Olig2) white matter (Fig-
ure 8D). In contrast, we did not detect changes in activated
caspase-3 expression in the embryonic spinal cord (data not
shown). Together, these results suggest that ERK1/2 is critical
for the proliferation, but not the survival of oligodendrocyte
progenitors.
In striking contrast to ERK1/2 regulation of the Schwann cell
lineage, Erk1/2 deleted oligodendrocytes were capable of mye-
lination. The early lethality of Erk1/2CKO(Olig2) mice limited our
analysis to only the initial stages of myelination, however, a clear
increase inMBP labeling is apparent in P1 Erk1/2CKO(Olig2) ventral
spinal cords (Figures 8E and 8F). S100b labeled oligodendro-
cytes in the white matter of mutant embryos exhibited a more
ramified, complex morphology than controls, further suggesting
that loss of Erk1/2 triggered premature differentiation (Figures 8Afound in mutant nerves. Note the decreased nerve caliber in mutants. Since
Schwann cell number is not altered, the density of nuclei is increased.
See also Figure S5.
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Figure 6. ERK1/2 Regulates the Expression of Genes Important for
Schwann Cell Progenitor Development and Myelination
(A) Two hundred nine genes met the criteria for differential expression in RNA
samples derived from E12.5 Erk1/2CKO(Wnt1) DRGs. The pie chart summarizes
the major functional categories represented by the differentially expressed
genes and the number downregulated (green) and upregulated (red) within
each category.
(B) Candidate geneswith known roles in glial development are differentially ex-
pressed in the DRG of Erk1/2CKO(Wnt1)embryos.
(C) qPCR analysis of E12.5 Erk1/2CKO(Wnt1) DRG samples validated the
decrease in the expression of transcription factors thought to regulate glial
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100 Neuron 69, 91–105, January 13, 2011 ª2011 Elsevier Inc.and 8B, data not shown). Coimmunostaining of MBP positive
cells with an ERK2 antibody confirmed that myelinating oligo-
dendrocytes were truly ERK1/2 deficient in mutants (Figures
S8C and S8D). These data show that, in contrast to Schwann
cells, myelination by oligodendrocytes can proceed in the
absence of Erk1/2.
DISCUSSION
We have assessed the functions of ERK1/2 and ERK5 in distinct
cell types during PNS development in vivo. Our data lead to
several clear conclusions. First, many aspects of embryonic
sensory and motor neuron development occur normally in the
setting of Erk1/2 deletion, although sensory axons do not invade
NGF-expressing target fields. Second, ERK5 does not appear to
strongly regulate embryonic PNS development. Third, ERK1/2 is
critical for fundamental aspects of Schwann cell development.
Erk1/2 deletion phenotypes resemble those of Nrg-1 and ErbB
mutants, and Erk1/2 deleted Schwann cell progenitors do not
respond to neuregulin-1. Finally, the requirement of ERK1/2 for
myelination is specific to Schwann cells, as myelination by oligo-
dendrocytes can proceed in the absence of Erk1/2. Overall, our
findings tightly link in vivo functions of ERK/MAPK signaling to
biological actions of specific RTK activating factors.
ERK/MAPK Signaling Is Dispensable for Many Aspects
of PNS Neuron Development
Gene targeting studies have defined roles for numerous trophic
factors, ECM molecules, and axon guidance cues in directing
PNS neuron development (Marmigere and Ernfors, 2007).
However, the signaling pathways mediating these effects
in vivo have not been defined. Many growth promoting cues
appear to converge upon ERK1/2, and combinations of trophic
stimuli, such as integrins and growth factors, trigger synergistic
ERK1/2 activation (Perron and Bixby, 1999). Overall, these
data predict that ERK1/2 is a central regulator of neuronal
morphology and development in vivo.
In spite of a wealth of in vitro data, our in vivo findings provide
surprisingly little support for a broad and essential role for
ERK1/2 for the acquisition of neuronal phenotypes, survival, or
initial axon outgrowth. Our results instead show that ERK1/2
signaling is required for NGF-mediated cutaneous sensory
neuron innervation at late embryonic and early postnatal stages.
These results are generally consistent with previous findings in
B-Raf/C-Raf and SRF conditional knockout mice (Wickrama-
singhe et al., 2008; Zhong et al., 2007) and in line with the estab-
lished role for NGF/TrkA signaling in promoting the formation and
maintenance of these afferents (Patel et al., 2000). The peripheral
nerve defect is not as severe as that reported in TrkA/Baxmutant
mice, suggesting a contribution to morphological development
by other pathways, such as PI3K and PLC (Patel et al., 2000).
Overall, our results establish that ERK1/2 signaling in vivo is
required to transduce the morphological effects of skin deriveddevelopment. Interestingly, the myelin components, MBP and MAG, show
increased expression in mutant DRGs. (n = 4; *p value < 0.05).
See also Figure S6.
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Figure 7. Spinal Motor Neuron Peripheral
Innervation Is Not Regulated by ERK1/2
Signaling
(A and B) Whole-mount immunostaining of
E14.5 TauSTOP forelimbs from control (A) and
Erk1/2CKO(Olig2) (B) embryos did not reveal any
difference in the initial growth of motor neuron
peripheral projections.
(C–F) The pattern of motor innervation of NMJs in
the P1 soleus (C and D) and diaphragm (E and F)
was not altered in Erk1/2CKO(Olig2) (D and F) em-
bryos relative to controls (C and E).
See also Figure S7.
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Specific Functions for ERK/MAPK in PNS DevelopmentNGF. However, neuronal ERK/MAPK signaling is surprisingly
dispensable for early phases of neuronal differentiation, neuronal
survival, long range axon growth, and formation of the neuro-
muscular junction.
Another surprise relates to the apparently limited role of ERK5.
ERK5 has been convincingly established as a retrograde survival
signal for NGF-stimulated DRG and sympathetic ganglion
neurons in vitro (Finegan et al., 2009; Watson et al., 2001). The
reason for the discrepancy between in vitro and in vivo findings
related to ERK5 mediated survival functions remains elusive.
ERK5 and ERK1/2 exhibit some overlap in downstream targets,
opening the possibility of a compensatory interaction. However,
the drastically different phenotypes and mechanisms leading to
lethality in Erk2/ versus Erk5/ embryos demonstrate that
ERK1/2 and ERK5 possess many unique, independent functions
(Nishimoto and Nishida, 2006). Our results with Erk1/ Erk2fl/fl
Erk5fl/fl Advillin:Cre mutants suggests that compensatory inter-
actions between these two cascades are minimal in sensory
neurons.
ERK1/2 Mediates Effects of Neuregulin-1 on Schwann
Cell Development
Although numerous extracellular factors that activate ERK1/2
are known to regulate Schwann cell development, the require-
ment for ERK1/2 signaling in mediating Schwann cell responses
has been controversial. Instead the PI3K/Akt pathway appears
to play a particularly prominent role (Harrisingh et al., 2004; Hu
et al., 2006; Li et al., 2001; Maurel and Salzer, 2000; Ogata
et al., 2004). An important caveat is that much of this prior
work regarding ERK1/2 signaling has relied upon varying
in vitro models, likely contributing to disparate conclusions.Neuron 69, 91–105Our data help resolve a longstanding
debate in establishing that ERK1/2 is
absolutely necessary for multiple stages
of Schwann cell development in vivo.
The neuregulin/ErbB axis is critical for
Schwann cell development (Birchmeier
and Nave, 2008). The signaling pathways
required to mediate neuregulin functions
have been of intense interest, particularly
in relation to the control of myelination
(Grossmann et al., 2009; Kao et al.,
2009). Our data, taken together with other
lines of evidence, strongly suggest thatERK1/2 is a key signaling pathway necessary to transduce effects
of neuregulin-1 on Schwann cells in vivo. The phenotypes in
Erk1/2 and Nrg-1/ErbB mutant mice are remarkably similar. The
Erk1/2CKO(Wnt1) mice that we report here, and ErbB2/,
ErbB3/, and NRG-1/ mice previously reported, all exhibit
a near complete absence of SCPs in the peripheral nerve by
E12.5, yet satellite glia appear to be relatively unaffected (Meyer
and Birchmeier, 1995; Morris et al., 1999; Riethmacher et al.,
1997; Woldeyesus et al., 1999). The loss of SCPs in developing
peripheral nerve results in axon defasciculation, the subsequent
loss of all peripheral axon projections, and neuronal death,
a phenotype observed in other mouse models lacking SCPs,
such as Sox10/ (Britsch et al., 2001). Inhibition of Schwann
cell myelination is also present in both Erk1/2CKO(Dhh) and condi-
tional ErbB mutant mice, where gene inactivation occurs after
SCP’s have been specified in immature Schwann cells (Garratt
et al., 2000). Inactivation ofShp2, an ERK1/2 pathway activator re-
cruited by ErbB, results in similar disruptions in Schwann cell
development (Grossmann et al., 2009). Indeed, the defects in
Shp2 mutant Schwann cells in vitro correlated with decreased
sustained ERK1/2, but not PI3K/Akt, activity (Grossmann et al.,
2009). Finally, we demonstrate here that loss of ERK1/2 in glial
progenitors blocks the effects of neuregulin-1 in vitro. These
data establish that ERK1/2 is necessary to transduce neuregu-
lin-1/ErbB signals during the development of the Schwann cell
lineage in vivo.
Mechanisms and Specificity of the ERK1/2 Requirement
for Myelination
The precise mechanisms underlying the failed development of
Schwann cells in Erk1/2 mutant mice are likely complex given, January 13, 2011 ª2011 Elsevier Inc. 101
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Figure 8. ERK1/2 Signaling Is Necessary for
Oligodendrocyte Precursor Proliferation
but Is Not Required for Myelination
(A and B) Relative to controls (A) the number of
oligodendrocytes in the spinal cord ventral white
matter of P1 Erk1/2CKO(Olig2) (B) embryos is
strongly reduced.
(C and D) Quantification of the relative decrease in
the number of nuclei and labeled oligodendro-
cytes in E14.5 and P1 Erk1/2CKO(Olig2) white matter
(C). The proportion of BrdU-labeled oligodendro-
cytes is significantly decreased in Erk1/2CKO(Olig2)
E14.5 embryos (D) (mean ± SEM; *p < 0.01).
(E and F) At P1, MBP immunolabeling indicates
that myelination has just initiated in a small propor-
tion of oligodendrocytes in the ventral spinal cord
of control mice (E) (arrows). In Erk1/2CKO(Olig2) (F)
littermates, there is a significant increase in the
number of oligodendrocytes that express MBP
(E) (arrows).
See also Figure S8.
Neuron
Specific Functions for ERK/MAPK in PNS Developmentthe extensive repertoire of ERK1/2 substrates and downstream
targets (Yoon and Seger, 2006). The loss of the gliogenic
boundary cap in Erk1/2CKO(Wnt1) mice presumably leads to
a reduction in SCPs in the peripheral nerve. This phenotype
may result from a direct defect in survival as demonstrated
in vitro, but may also involve aberrant differentiation. Expression
profiling of early glial progenitors in the Erk1/2CKO(Wnt1) DRG
demonstrates that ERK1/2 promotes the expression of Id2 and
Id4, genes that maintain pluripotency and regulate glial differen-
tiation (Marin-Husstege et al., 2006). Additionally, ERK1/2
signaling suppresses the expression of markers of mature glia,
MBP and MAG. One interpretation of these data is that loss of
Erk1/2 leads to premature differentiation. Thus, SCPs or the
BC may have lost the ability to maintain the progenitor state,
which contributes to their loss in Erk1/2CKO(Wnt1) embryos. Inter-
estingly, Erk1/2 deletion at a later stage of Schwann cell develop-
ment with Dhh:Cre did not result in a significant change in
Schwann cell number in the sciatic nerves. This stage dependent102 Neuron 69, 91–105, January 13, 2011 ª2011 Elsevier Inc.difference in the regulation of Schwann
cell development mirrors the increasingly
limited effects of ErbB2 deletion as devel-
opment proceeds (Atanasoski et al.,
2006; Garratt et al., 2000) and presum-
ably results from an uncoupling of
ERK1/2 from specific cellular functions.
How is it that ERK1/2 regulates myeli-
nation? Erk1/2CKO(Dhh) peripheral nerves
fail to express markers of mature
Schwann cells, such as S100b, and mye-
lination is severely inhibited. ERK1/2
regulation of Egr2/Krox-20might underlie
this Schwann-cell-specific phenotype.
Egr2/Krox-20 is a critical gene for
promoting Schwann cell myelination and
is mutated in a subset of patients with
Charcot-Marie-Tooth (CMT) disease
(Topilko et al., 1994; Warner et al.,1998). Mice expressing CMT-related, Egr2/Krox-20 mutations
exhibit hypomyelination and a temporal progression of behav-
ioral dysfunction and death that closely phenocopies the
Erk1/2CKO(Dhh) mice we report here (Baloh et al., 2009). In vitro
evidence demonstrates that Egr2/Krox-20 induction is down-
stream of ERK1/2 and neuregulin signaling (Murphy et al.,
1996; Parkinson et al., 2002). Our findings suggest this interac-
tion is relevant in vivo as Egr2/Krox-20 expression is strongly
reduced in Erk1/2 mutant mice.
An important and surprising finding is that the cellular mech-
anisms regulated by ERK1/2 vary depending on the type of
myelinating glia. We demonstrate that Erk1/2 deletion strongly
reduces oligodendrocyte progenitor proliferation. It is well es-
tablished that oligodendrocyte progenitor proliferation is regu-
lated by PDGF in vivo (Calver et al., 1998). PDGF acts through
the RTK, PDGF-Ra, and we hypothesize that in oligodendro-
cytes, PDGF effects on proliferation require ERK1/2 signaling.
Interestingly, some oligodendrocytes were generated and
Neuron
Specific Functions for ERK/MAPK in PNS Developmentindeed initiated the expression of MBP earlier than controls
and expressed markers of mature oligodendrocytes. The
premature differentiation observed in Erk1/2-deleted oligoden-
drocytes is consistent with data showing that oligodendrocyte
differentiation requires a downregulation of PDGF-Ra, and
a downregulation of ERK1/2 activity (Chew et al., 2010; Dugas
et al., 2010). Thus, in contrast to Schwann cells, Erk1/2 deleted
oligodendrocytes are able to myelinate axons. The conditional
ablation of the ERK1/2 upstream regulator, B-Raf, has been re-
ported to result in a strong reduction in the number of myelin-
ated fibers in the postnatal brain (Galabova-Kovacs et al.,
2008). However, ERK1/2 activation was not completely abol-
ished in these mice due to compensation by other Raf family
members and the connection between oligodendrocyte
precursor proliferation and the number of myelinated fibers
was not clearly drawn.ERK/MAPK Functions Are Linked to Specific RTK
Systems
Evidence from numerous in vitro systems has suggested that
ERK1/2 is activated or functionally required in response to
a very wide range of extracellular cues, including netrins, sema-
phorins, GPCR’s, trophic factors, hormones, and ECM mole-
cules (Raman et al., 2007). Thus, we might have predicted that
early Erk1/2 deletion in the developing nervous system would
lead to drastic phenotypes that reflect the inhibition of nearly
all receptor systems. Instead, our findings suggest ERK1/2
mediates effects of specific RTKs in vivo, including invasion of
cutaneous target fields (NGF/TrkA), Schwann cell development
(Neuregulin/ErbB), and oligodendrocyte proliferation (PDGF/
PDGF-Ra). Although this initial analysis is of necessity superficial
and many subtle roles for ERK1/2 signaling in vivo will certainly
be uncovered, our results do suggest caution in interpreting
in vitro results. At the very least, our work suggests that the ability
to induce transient ERK1/2 activation or block cellular functions
pharmacologically in a strongly reduced in vitro system is not
a strong predictor of the biological requirement for ERK/MAPK
signaling in vivo.Implications for Human Neurodevelopmental
Syndromes
Aberrant ERK1/2 signaling plays a primary role in a range of
human syndromes that affect the nervous system, particularly
the family of ‘‘neuro-cardio-facial-cutaneous’’ (NCFC) syndromes
(Bentires-Alj et al., 2006; Samuels et al., 2009).Wehavepreviously
demonstrated that ERK1/2 signaling is a critical regulator of neural
crest contributions to craniofacial and great vessel development
helping to explain the pathogenesis of these disorders (Newbern
et al., 2008). The NCFC spectrum includes neurofibromatosis
(NF), which exhibits an increased propensity to peripheral nerve
tumors of Schwann cell precursor origin. Importantly, NF type 1
is caused by mutations in the Ras-GAP, neurofibromin, which
leads to increased signaling through the ERK1/2 pathway. Our
data demonstrating a requirement for ERK/MAPK signaling at
multiple stages of Schwann cell development are consistent
with abnormalities in the intricate balance between differentiation
and proliferation that leads to tumors in these patients.EXPERIMENTAL PROCEDURES
Mutant Mice
Animal experiments were performed in accordance with protocols approved
by IACUC at UNCCH. Erk1/mice possess a neo insertion in exons 1 through
6 (Nekrasova et al., 2005). Erk2fl/fl mice contain loxp sites around exon 3
(Samuels et al., 2008). Mek1fl/fl mice possess a loxp flanked exon 3, while
Mek2/ mice contain a neo insertion in exons 4–6 and were kindly provided
by Dr. J. Charron (Belanger et al., 2003; Bissonauth et al., 2006). TheWnt1:Cre
andNestin:Cremice were purchased from Jackson Laboratories. TheDhh:Cre
mouse was generously provided by Dr. D. Meijer and the Olig2:Cremouse by
Dr. T. Jessell. For the Erk5 floxed allele, a targeting vector was generated
based on an Erk5 fragment derived from a 129 Sv genomic BAC library and
incorporated loxp sites around Exon 3 (Figures S1K and S1L). All mice were
of mixed genetic background. For BrdU injections, timed pregnant dams
were injected at E14.5 with 75 mg/kg BrdU and sacrificed 4 hr later. For timed
breedings, the appearance of a vaginal plug was considered to be E0.5 on the
day of detection. All experiments were replicated at least three times withmice
derived from independent litters. Cre-expressing littermates were utilized as
control embryos for most experiments. Further detail regarding the Erk5 floxed
mouse and genotyping is listed in Supplemental Experimental Procedures.
Western Blotting
Western blotting was performed according to a standard protocol outlined in
Supplemental Experimental Procedures. The primary antibodies used
were anti-phospho or pan ERK1/2, anti-ERK5, anti-phospho-RSK3, anti-
cleaved Caspase-3, anti-MEK1/2, and anti-GAPDH (all from Cell Signaling
Technologies).
Immunohistochemistry
Paraformaldehyde-fixed, cryopreserved specimens were immunostained
according to standard procedures and imaged with a Zeiss LSM 510 NLO
confocal microscope. Further detail regarding immunohistochemistry, primary
antibodies, whole-mount staining, and counting methods are described in
Supplemental Experimental Procedures.
Electron Microscopy
Mice were anesthetized and perfused with 2% paraformaldehyde and 2.5%
glutaraldehyde in 0.1 M cacodylate buffer. A 2–3 mm section of the sciatic
nerve, proximal to the division into the cutaneous and tibial nerve, was
dissected, rinsed, and postfixed overnight at 4C and prepared for EM as
described in Supplemental Experimental Procedures.
Tissue Culture
Embryonic DRGs were cultured as previously described with minor modifica-
tions (Markus et al., 2002) as described in Supplemental Experimental
Procedures.
RNA Extraction and Analysis
E12.5 DRGs from control and Erk1/2CKO(Wnt1) embryos derived from three
independent litters were dissected in PBS supplemented with 10% RNAlater
(QIAGEN) and frozen on dry ice. Total RNA was extracted with Trizol (Invitro-
gen) and a QIAGEN RNeasy Mini kit per manufacturer’s instructions. RNA
samples for were assayed for quality and quantity with an Agilent 2100 Bioa-
nalyzer and a Nanodrop spectrophotometer. Total RNA was amplified,
labeled, and hybridized on Illumina arrays (MouseRef-8 V2 Expression Bead-
Chip, Illumina). Slides were processed and scanned in an Illumina BeadStation
platform according to the manufacturer protocol. Data was further processed
using quantile normalization. Log2 ratios and p values are calculated in R from
a Bayesian moderated t test using the LIMMA package. Regulated transcripts
were defined by a greater than 1.5-fold change and a p value less than 0.05.
Functional annotation of differentially expressed genes was obtained through
the use of The Ingenuity Pathways KnowledgeBase (Ingenuity Systems, http://
www.ingenuity.com), The Database for Annotation, Visualization and Inte-
grated Discovery (http://david.abcc.ncifcrf.gov), the Gene Ontology Project
(http://www.geneontology.org), and extensive literature review. MicroarrayNeuron 69, 91–105, January 13, 2011 ª2011 Elsevier Inc. 103
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Specific Functions for ERK/MAPK in PNS Developmentdata are deposited in NCBI GEO database #GSE24730. Further detail
regarding qPCR is listed in Supplemental Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/j.
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